Golzar Hemmati

Statistics

Publications

Citations

H-Index

Active since

2016

Affiliations

University of California, San Francisco(Current)

UCSF Helen Diller Family Comprehensive Cancer Center

Rapt Therapeutics (United States)

Revolution Medicines (United States)

Golzar Hemmati is an author at University of California, San Francisco specializing in oncology, molecular oncology, and oncogenic signaling pathways.

ORCID

Publications per year

2016–2024

Publications

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

Robert J. Nichols, Franziska Haderk, Carlos Stahlhut et al. · Nature Cell Biology · 2018 · 418 citations

Medicine, Molecular Biology, Oncology +16

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

Khyati N. Shah, Roma Bhatt, Julia Rotow et al. · Nature Medicine · 2018 · 286 citations · Full text

Medicine, Molecular Biology, Oncology +14

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins

Dana S. Neel, David V. Allegakoen, Victor Olivas et al. · Cancer Research · 2018 · 96 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase <i>BRAF</i> -mutant lung cancer

Ross A. Okimoto, Luping Lin, Victor Olivas et al. · Proceedings of the National Academy of Sciences · 2016 · 77 citations · Full text

Medicine, Oncology, Pharmacology +17

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer

Joyce V. Lee, Filomena Housley, Christina Yau et al. · Nature Communications · 2022 · 75 citations · Full text

Life Sciences, Immunology, Oncology +17

1–5 of 9